By Mill Chart
Last update: Nov 24, 2023
Our stockscreener has identified a possible breakout setup on BIOHAVEN LTD (NYSE:BHVN). This occurs when the stock consolidates following a significant upward movement. While the breakout outcome cannot be guaranteed, it may be worth monitoring NYSE:BHVN for potential opportunities.
ChartMill assigns a Technical Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple technical indicators and properties.
We assign a technical rating of 9 out of 10 to BHVN. This is due to a consistent performance in both the short and longer term time frames. Also compared to the overall market, BHVN is showing a nice and steady performance.
For an up to date full technical analysis you can check the technical report of BHVN
ChartMill incorporates a Setup Rating in its analysis, which measures the extent of consolidation in a stock over recent days and weeks. This rating, ranging from 0 to 10, is updated daily and takes into account multiple short-term technical indicators. The current setup rating for NYSE:BHVN is 8:
BHVN has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is a resistance zone just above the current price starting at 30.82. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 29.52, a Stop Loss order could be placed below this zone. Very recently a Pocket Pivot signal was observed. This is another positive sign.
One way to play this would be to wait for the actual breakout to happen and buy when the stock breaks out above the current consolidation zone. A possible place for a stop loss would be below this zone.
Disclaimer: This article is not intended to provide trading advice. It is crucial to conduct your own analysis and consider your own observations and trading style when making investment decisions. The article solely presents technical observations and should not be relied upon as a sole basis for trading.
Every day, new breakout setups can be found on ChartMill in our Breakout screener.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
NYSE:BHVN (2/22/2024, 10:06:37 AM)
RBC Capital Markets has initiated coverage of Biohaven (BHVN) with an outperform rating, citing the company’s epilepsy drug candidate BHV-7000 and business stra
UBS has initiated coverage of Biohaven (BHVN) with a buy rating, citing its attractive valuation and diverse pipeline. The investment bank said it was “bullish
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 42nd Annual J.P....
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses...
Biohaven reported Q3 2023 financial results with a non-GAAP EPS of -$1.44. Shares declined by 0.34% after hours.
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023, which included net proceeds of $242...
- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...
Biohaven raised $258.7M in recent public offering, selling 11.76M shares at $22 per share, which include the full exercise of the underwriters' option.